BESREMi is indicated to treat polycythemia vera, a rare type of blood cancer. Credit: Kateryna Kon via Shutterstock.com.

PharmaEssentia has chosen Pint-Pharma as commercial partner for BESREMi (ropeginterferon alfa-2b-NJFT) in Latin America.

The companies have entered into an exclusive licence agreement to register and promote BESREMi to treat polycythemia vera (PV), a rare type of blood cancer, in Ecuador, Chile, Mexico, Argentina, Brazil, Colombia and Peru.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

PharmaEssentia may be entitled to receive certain milestone payments along with royalties based on sales of the product.

Pint-Pharma will obtain and maintain all marketing authorisations and will commercialise BESREMi in the region.

PharmaEssentia founder and CEO Ko-Chung Lin stated: “Expanding our geographic reach is critical to our mission to address clear gaps in therapeutic options for people with myeloproliferative neoplasms (MPNs).

“This regional expansion is a logical extension of our growing leadership in the Americas, led by Meredith Manning.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Pint-Pharma has experience in registering and commercialising oncology, rare disease and speciality therapeutics throughout Latin America.

Pint-Pharma CEO David Munoz stated: “Our partnership with PharmaEssentia gives us the opportunity to provide another new treatment option to people living with MPNs in the region who are in need of effective therapies.

“We look forward to the potential to add BESREMi to our established haemato-oncology portfolio.”

BESREMi is a monopegylated long-acting interferon that has a long duration of activity in the body and uses pegylation technology.

It holds orphan drug designation in the US to treat PV.

In 2019, the European Medicines Agency approved the therapy, which has also been licensed in Japan, Taiwan and South Korea.